tiprankstipranks
Trending News
More News >
Inhibitor Therapeutics Inc. (INTI)
OTHER OTC:INTI
US Market

Inhibitor Therapeutics (INTI) Income Statement

Compare
29 Followers

Inhibitor Therapeutics Income Statement

Last quarter (Q1 2025), Inhibitor Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q1, Inhibitor Therapeutics's net income was $-633.00K. See Inhibitor Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 3.66M$ 3.40M$ 657.93K$ 325.39K$ 1.06M
Depreciation and Amortization
$ 3.66M$ 3.40M$ 657.93K$ 325.39K$ 1.06M
EBITDA
$ -3.34M$ 378.84K$ -658.00K$ -325.00K$ -1.06M
Operating Income
$ -3.66M$ -3.40M$ -658.00K$ -325.00K$ -1.06M
Other Income/Expenses
$ 318.21K$ 378.84K$ 12.82M$ 26.76K$ 1.07K
Pretax Income
$ -3.34M$ -3.03M$ 12.16M$ -299.00K$ -1.06M
Net Income
$ -3.34M$ -3.03M$ 12.11M$ -299.00K$ -1.06M
Per Share Metrics
Basic EPS
$ -0.02$ -0.02$ 0.03$ 0.00$ 0.00
Diluted EPS
$ -0.02$ -0.02$ 0.03$ 0.00$ 0.00
Weighted Average Shares Outstanding
172.26M 151.31M 366.18M 376.25M 371.93M
Weighted Average Shares Outstanding (Diluted)
172.26M 171.95M 367.78M 376.25M 371.93M
Currency in USD

Inhibitor Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis